Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)

Templeton, Arnoud J; Dutoit Vallotton, Valérie; Cathomas, Richard; Rothermundt, Christian; Bärtschi, Daniela; Dröge, Cornelia; Gautschi, Oliver; Borner, Markus; Fechter, Eva; Stenner, Frank; Winterhalder, Ralph; Müller, Beat; Schiess, Ralph; Wild, Peter J; Rüschoff, Jan H; Thalmann, George; Dietrich, Pierre-Yves; Aebersold, Ruedi; Klingbiel, Dirk; Gillessen, Silke

doi:10.1016/j.eururo.2013.03.040

Article scientifique

Anglais

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)

Publié dansEuropean urology, vol. 64, no. 1, p. 150-158

Date de publication2013

Résumé

The phosphatase and tensin homolog (PTEN) tumor suppressor gene is deregulated in many advanced prostate cancers, leading to activation of the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway and thus increased cell survival.

Structure d'affiliation

Faculté de médecine / Section de médecine clinique / Département de médecine

Groupe de recherche

Immunothérapie des cancers (42)

Citation (format ISO)

TEMPLETON, Arnoud J et al. Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08). In: European urology, 2013, vol. 64, n° 1, p. 150–158. doi: 10.1016/j.eururo.2013.03.040

Article (Published version)

Identifiants

PID : unige:33771
DOI : 10.1016/j.eururo.2013.03.040
PMID : 23582881

ISSN du journal0302-2838

512vues

0téléchargements

Création12/12/2013 22:40:00

Première validation12/12/2013 22:40:00

Heure de mise à jour14/03/2023 20:54:35

Changement de statut14/03/2023 20:54:34

Dernière indexation16/01/2024 14:02:43

Archive ouverte UNIGE

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)

The phosphatase and tensin homolog (PTEN) tumor suppressor gene is deregulated in many advanced prostate cancers, leading to activation of the phosphatidylinositol 3-kinase (PI3K)-Akt-mammalian target of rapamycin (mTOR) pathway and thus increased cell survival.

Informations techniques